| Autor: |
MAZLAN-KEPLI, WARDATI, LAI WAN MAE, MALEK, ABDUL MUIZZ ABDUL, CHIA CHUN HOU, WINNIE NEOH TZE SHIN |
| Předmět: |
|
| Zdroj: |
International Journal of Pharmaceutical Research (09752366); Apr-Jun2021, Vol. 13 Issue 2, p3252-3259, 8p |
| Abstrakt: |
Background: Proton pump inhibitor (PPI) is recommended for patients on dual antiplatelet (DAPT) therapy with a history of prior gastrointestinal bleeding and those with multiple risk factors for GI bleeding. Several studies revealed that a large proportion of patients had no evidence-based indication for using PPI. However, there is a research gap in PPI prescribing among acute coronary syndrome (ACS) patients in Malaysia. This study aimed to determine the prevalence of PPI prescribing among ACS patients in Hospital Serdang and the predictors of PPI prescribing in this population. Results: Out of 467 patients (77.5 % male; mean age 57.0 (12.5) years), 36.4% (n=170) were prescribed with PPI during hospitalization. Of the 436 patients (77.1% male; mean age 56.7 (12.5) years) who were successfully discharged, 37.8% (n=165) were prescribed with PPI at discharge. Predictors of PPI during hospitalization and at discharge were similar including types of ACS in relation to unstable angina i.e. ST-elevation myocardial infarction (MI), low hemoglobin during admission and medicated with PPI before admission. On the other hand, concomitant anticoagulant, antiplatelet and DAPT were not predictors of PPI during hospitalization and at discharge. Conclusion: The prescribing of PPI during hospitalization and at discharge following ACS is modest, although it increased based on the type of MI, low hemoglobin during admission and whether patient was previously prescribed with PPI. We suggest larger studies to identify bleeding risks, and to explore practitioners' awareness on PPI prescribing to optimize PPI prescriptions in future. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
